AACE 2026
Summaries from AACE 2026 Annual Meeting, held from April 22 – 24, 2026.
Wernicke encephalopathy emerges as a possible safety signal in patients on GLP-1 receptor agonists, analysis suggests
Presenter: Manar Kadhem, MD, Mansoura University, Mansoura, Egypt
Wernicke encephalopathy in patients treated with glucagon-like peptide-1 receptor agonists: a comprehensive systematic review. Presented April 23, 2026.
Markers of hypercortisolism and primary aldosteronism may co-occur in patients with resistant hypertension, MOMENTUM analysis shows
Presenter: Lance A. Sloan, MD, MSE, Texas Institute for Kidney and Endocrine Disorders, Lufkin, TX
Co-secretion of cortisol and aldosterone in individuals with resistant hypertension: results from the MOMENTUM trial. Presented April 24, 2026.
Fatty liver disease may increase hip and humerus fracture risk in men, cohort study suggests
Presenter: Yonghwan Kim, MD, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Republic of Korea
Association between metabolic dysfunction-associated steatotic liver disease and osteoporotic fracture risk in Korean adults: a nationwide cohort study. Presented April 23, 2026.
Teplizumab has a manageable safety profile in stage 2 and stage 3 type 1 diabetes, meta-analysis suggests
Presenter: Andressa Frankowski Dagostin, MD, San Raffaele University, Milan, Italy
Safety profile of teplizumab in stage 2 and stage 3 type 1 diabetes: a single-arm systematic review and meta-analysis of adverse events. Presented April 23, 2026.
Asymmetry in adrenal gland volume predicts postoperative adrenal insufficiency in patients with bilateral macronodular adrenal hyperplasia, study shows
Presenter: Kelcie Lushefski, MD, Mayo Clinic, Rochester, MN
Volume of resected adrenal gland predicts development of adrenal insufficiency in patients with bilateral macronodular adrenal hyperplasia (BMAH). Presented April 24, 2026.
In advanced thyroid cancer, lenvatinib offers similar survival but more hypertension and proteinuria vs other systemic therapies, real-world analysis suggests
Presenter: Eleana Estrella, DO, University of Central Florida, Orlando, FL
Five-year survival and toxicity of lenvatinib versus other systemic therapies in thyroid cancer: a propensity-matched real-world TriNetX study. Presented April 23, 2026.
Computerized intravenous insulin algorithm virtually eliminates severe hypoglycemia across 19 hospitals, analysis suggests
Presenter: Joseph Aloi, MD, Advocate Health, Wake Forest Baptist Hospital, Winston-Salem, NC
Virtual elimination of severe hypoglycemia utilizing a computerized insulin dosing algorithm for intravenous insulin infusions. Presented April 23, 2026.
Adrenal venous sampling identifies surgical candidates missed by imaging in ACTH-independent autonomous cortisol secretion, analysis suggests
Presenter: Tetsuya Kawahara, MD, PhD, Shinkomonji Hospital, Kitakyushu, Japan
Adrenal venous sampling improves functional lateralization in adrenocorticotropic hormone-independent autonomous cortisol secretion with non-decisive imaging. Presented April 23, 2026.
Tirzepatide use linked to lower mortality, improved cardiometabolic outcomes vs semaglutide in obese patients with hypothyroidism
Presenter: Andrew Cecil, DO, MS, Advocate Aurora Health Care
Cardiovascular, metabolic, and mortality outcomes with semaglutide versus tirzepatide in obese patients with hypothyroidism: a real-world analysis. Presented April 23, 2026.